Evidence map›Paper›PMID 27855167›Full record

ArticlePloS one2016

Assessment of Olfactory Function in MAPT-Associated Neurodegenerative Disease Reveals Odor-Identification Irreproducibility as a Non-Disease-Specific, General Characteristic of Olfactory Dysfunction.

Katerina Markopoulou, Bruce A Chase, Piotr Robowski, Audrey Strongosky, Ewa Narożańska, Emilia J Sitek, Mariusz Berdynski, Maria Barcikowska, Matt C Baker, Rosa Rademakers and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Olfactory Testing in Frontotemporal Dementia: A Literature Review.American journal of Alzheimer's disease and other dementias · 2018
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Katerina MarkopoulouNorthShore University Health System, Evanston, Illinois, United States of America.ORCID http://orcid.org/0000-0003-3973-5437
Bruce A ChaseDepartment of Biology, University of Nebraska at Omaha, Omaha, Nebraska, United States of America.
Piotr RobowskiDepartment of Neurological and Psychiatric Nursing, Medical University of Gdańsk, Gdańsk, Poland.
Audrey StrongoskyDepartment of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, Florida, United States of America.
Ewa NarożańskaDepartment of Neurological and Psychiatric Nursing, Medical University of Gdańsk, Gdańsk, Poland.
Emilia J SitekDepartment of Neurological and Psychiatric Nursing, Medical University of Gdańsk, Gdańsk, Poland.
Mariusz BerdynskiDepartment of Neurodegenerative Disorders, Mossakowski Medical Research Center, Polish Academy of Sciences, Warsaw, Poland.
Maria BarcikowskaDepartment of Neurodegenerative Disorders, Mossakowski Medical Research Center, Polish Academy of Sciences, Warsaw, Poland.
Matt C BakerDepartment of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, Florida, United States of America.
Rosa RademakersDepartment of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, Florida, United States of America.
Jarosław SławekDepartment of Neurological and Psychiatric Nursing, Medical University of Gdańsk, Gdańsk, Poland.
Christine KleinInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Katja HückelheimInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Meike KastenInstitute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic Jacksonville, Jacksonville, Florida, United States of America.
Copernicus Memorial Hospital · PLJacksonville College · USUniversity of Lübeck · DEPolish Academy of Sciences · PLNorthShore University HealthSystem · USUniversity of Nebraska at Omaha · US

Funding

THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
Neuropathology CoreP50NS072187 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM · 2010 to 2017
$8.7M
Biomarkers for Preclinical Parkinson's diseaseR01NS057567 · NINDS · UNIVERSITY OF WASHINGTON · PI ZHANG, JING · 2008 to 2012
$3.1M
The genetics of chromosome 17q21-linked tau-negative FTDR01AG026251 · NIA · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2006 to 2014
$1.9M
GGGGCC hexanucleotide repeat expansions in neurodegenerative diseaseR01NS080882 · NINDS · MAYO CLINIC JACKSONVILLE · PI RADEMAKERS, ROSA · 2012 to 2016
$1.6M
Molecular genetic studies of progranulin regulators in FTLD and ALSR01NS076471 · NINDS · MAYO CLINIC JACKSONVILLE · PI RADEMAKERS, ROSA · 2013 to 2016
$1.4M
Progranulin: Mutation and Regulation in Neurodegenerative diseaseR01NS065782 · NINDS · MAYO CLINIC JACKSONVILLE · PI RADEMAKERS, ROSA · 2009 to 2012
$1.3M
NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG026251NINDS NIH HHS P50 NS072187NINDS NIH HHS R01 NS057567NINDS NIH HHS R01 NS065782NINDS NIH HHS R01 NS076471NINDS NIH HHS R01 NS080882
6 · The paper itself

Abstract

Olfactory dysfunction is associated with normal aging, multiple neurodegenerative disorders, including Parkinson's disease, Lewy body disease and Alzheimer's disease, and other diseases such as diabetes, sleep apnea and the autoimmune disease myasthenia gravis. The wide spectrum of neurodegenerative disorders associated with olfactory dysfunction suggests different, potentially overlapping, underlying pathophysiologies. Studying olfactory dysfunction in presymptomatic carriers of mutations known to cause familial parkinsonism provides unique opportunities to understand the role of genetic factors, delineate the salient characteristics of the onset of olfactory dysfunction, and understand when it starts relative to motor and cognitive symptoms. We evaluated olfactory dysfunction in 28 carriers of two MAPT mutations (p.N279K, p.P301L), which cause frontotemporal dementia with parkinsonism, using the University of Pennsylvania Smell Identification Test. Olfactory dysfunction in carriers does not appear to be allele specific, but is strongly age-dependent and precedes symptomatic onset. Severe olfactory dysfunction, however, is not a fully penetrant trait at the time of symptom onset. Principal component analysis revealed that olfactory dysfunction is not odor-class specific, even though individual odor responses cluster kindred members according to genetic and disease status. Strikingly, carriers with incipient olfactory dysfunction show poor inter-test consistency among the sets of odors identified incorrectly in successive replicate tests, even before severe olfactory dysfunction appears. Furthermore, when 78 individuals without neurodegenerative disease and 14 individuals with sporadic Parkinson's disease were evaluated twice at a one-year interval using the Brief Smell Identification Test, the majority also showed inconsistency in the sets of odors they identified incorrectly, independent of age and cognitive status. While these findings may reflect the limitations of these tests used and the sample sizes, olfactory dysfunction appears to be associated with the inability to identify odors reliably and consistently, not with the loss of an ability to identify specific odors. Irreproducibility in odor identification appears to be a non-disease-specific, general feature of olfactory dysfunction that is accelerated or accentuated in neurodegenerative disease. It may reflect a fundamental organizational principle of the olfactory system, which is more "error-prone" than other sensory systems.

Indexed as

MutationAdultAge of OnsetAllelesFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansMaleMiddle AgedNeurodegenerative DiseasesOdorantsOlfaction DisordersQuantitative Trait, HeritableSeverity of Illness IndexSmellMAPT protein, humantau Proteins

Identifiers

PMID27855167
PMCPMC5113898
OpenAlexW2555143230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.